- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07673055
High-frequency Short-course Extracorporeal Shock Wave Therapy for Partial Rotator Cuff Tears: Study Protocol for a Multicenter, Randomized, Controlled Trial
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Study Background Partial rotator cuff tears are extremely prevalent musculoskeletal disorders, affecting 20-30% of the general population and over 40% of people aged 60 and above. The condition causes persistent shoulder pain, night pain and restricted shoulder movement, interfering with daily activities and quality of life. International clinical guidelines recommend conservative treatment as the first choice for this disease to avoid surgical risks such as infection and tissue adhesion.
Extracorporeal shock wave therapy (ESWT) is a widely used non-invasive physical therapy for tendon injuries. It promotes blood circulation, tendon repair and pain relief. However, the conventional low-frequency ESWT plan (one session per week for 7 weeks) has obvious drawbacks: slow symptom relief, long treatment cycle and poor patient adherence. Early single-center research has confirmed that a daily high-frequency short-course ESWT works better for pain control, functional recovery and tendon healing, with good safety. This formal multicenter trial is designed to verify these findings and further optimize treatment protocols.
Study Objectives Primary goal: Compare the efficacy of two high-frequency ESWT regimens and the conventional regimen in reducing shoulder pain of patients with partial rotator cuff tears at 3 months after treatment.
Secondary goals: Evaluate the improvements of shoulder joint function and range of motion; use MRI and ultrasound to objectively assess tendon repair status; analyze patient treatment compliance and incidence of adverse reactions; develop an optimized, evidence-based ESWT standard protocol for clinical promotion.
Study Design & Participants Study Design This is a prospective, multicenter, three-arm parallel-group randomized controlled trial with outcome assessor blinding. Participants will be randomly divided into three groups at a 1:1:1 ratio. All treatment groups adopt identical ESWT technical parameters: 2000 shocks per session, 10 Hz frequency, energy flux density of 0.1-0.25 mJ/mm².
Three Treatment Groups Group 1 (High-frequency short-course group): Receive ESWT once a day for 7 consecutive days (7 sessions in total within 1 week).
Group 2 (High-frequency intensive group): Complete 3 treatment cycles. Each cycle includes 7 consecutive daily ESWT sessions, with a 1-week rest between cycles (21 sessions in total within 7 weeks).
Group 3 (Conventional group/control): Receive ESWT once a week for 7 consecutive weeks (7 sessions in total within 7 weeks).
Eligibility Criteria Inclusion Criteria Aged 30 to 70 years, regardless of gender. Diagnosed with partial-thickness rotator cuff tear or small non-retracted full-thickness rotator cuff tear via MRI or high-resolution ultrasound.
Shoulder pain lasting for at least 3 months, with a pain score (VAS) of 4 points or higher (0-10 scale).
Voluntarily join the study and sign written informed consent, and agree to complete all treatments and follow-up visits.
Exclusion Criteria Severe full-thickness rotator cuff tear, tendon retraction above Grade II, or greater tuberosity bone cyst.
Severe muscle fatty infiltration of the shoulder (Goutallier grade ≥3) shown on MRI.
Poorly controlled diabetes, hypothyroidism, or heavy long-term smoking. Received local injections (corticosteroids, platelet-rich plasma etc.) on the affected shoulder within the past 4 weeks.
Combined with severe shoulder osteoarthritis, frozen shoulder, shoulder instability, rheumatoid arthritis, bleeding disorders or coagulation problems.
Pregnant or breastfeeding women; patients with cardiac pacemakers or tumors at the treatment site (contraindications for ESWT).
Unable to finish the full course of treatment or follow-up arrangements. Recruitment Scale & Centers A maximum of 300 participants will be enrolled from 10 tertiary hospitals nationwide, including Peking University Third Hospital, Beijing Chao-Yang Hospital, West China Hospital of Sichuan University and other renowned medical institutions. The recruitment period lasts from January 2026 to December 2027.
Combined Care & Follow-up Arrangements All participants will receive unified guidance on daily activity adjustment and home rehabilitation exercises. Oral pain-relieving anti-inflammatory drugs are allowed and will be recorded, while other physical therapies (ultrasound, laser, massage etc.) are prohibited during treatment.
Follow-up time points: Baseline (before treatment), 3 months, 6 months and 12 months after treatment. At each follow-up, researchers will assess pain degree, shoulder function and joint mobility. MRI and ultrasound re-examinations will be conducted at baseline, 6 months and 12 months to evaluate tendon healing. All adverse reactions during treatment and follow-up will be recorded in detail.
Evaluation Indicators Primary indicator: Changes of shoulder pain score (VAS) from baseline to 3 months after intervention.
Secondary indicators:
Shoulder function scores (ASES, Constant-Murley Score) and active/passive joint range of motion.
Imaging indicators: Changes of tendon signal-to-noise ratio, tear size and tendon thickness detected by MRI and ultrasound.
Treatment adherence: The proportion of participants who complete the scheduled treatment sessions.
Safety indicators: Types, quantity and severity of adverse events (local redness, swelling, skin petechiae, transient pain aggravation etc.).
Patients' overall subjective evaluation of symptom improvement.
Study Strengths & Implementation Notes To avoid assessment bias, the staff responsible for evaluating curative effects and reading imaging images will not know which treatment group each participant belongs to.
All operating procedures, assessment standards and imaging measurement methods are unified across all participating hospitals to ensure data accuracy and consistency.
This study is the first multicenter trial comparing high-frequency short-course ESWT and conventional regimens for partial rotator cuff tears. It combines subjective symptom scores and objective imaging biomarkers to obtain reliable clinical evidence.
After the trial ends, the research team will form a set of optimized ESWT application specifications, which will be promoted to clinical departments such as rehabilitation and sports medicine to provide a better non-surgical treatment option for patients with partial rotator cuff tears.
- Ethical Statement The study strictly follows the Declaration of Helsinki and clinical trial norms. The protocol has passed the ethical review of all participating hospitals. All participants have the right to withdraw from the study at any time without penalty. Personal medical information of all participants will be encrypted and kept confidential to protect privacy.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Xiali Xue, Dr
- Telefoonnummer: +86 18483638915
- E-mail: 390231882@qq.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age 30-70 years, male or female
- MRI- or high-resolution ultrasound-confirmed partial-thickness rotator cuff tear (predominantly supraspinatus) or small full-thickness tear without retraction or displacement
- Shoulder pain duration ≥3 months with Visual Analog Scale (VAS) score ≥4 (0-10 scale)
- Willing and able to provide written informed consent and comply with the study protocol
Exclusion Criteria:
- Large or massive full-thickness rotator cuff tear, tear with Grade II retraction or greater, or presence of a greater tuberosity bone cyst
- Severe muscle fatty infiltration (Goutallier grade ≥3) on MRI
- Uncontrolled diabetes mellitus (HbA1c >7.5%), hypothyroidism, or heavy smoking (≥20 pack-years)
- Received local injection therapy (e.g., corticosteroids, platelet-rich plasma) to the affected shoulder within 4 weeks prior to enrollment
- Concurrent shoulder pathologies including glenohumeral osteoarthritis, adhesive capsulitis (frozen shoulder), or shoulder instability
- Systemic diseases (e.g., rheumatoid arthritis), bleeding disorders, or coagulopathy
- Pregnancy or lactation
- Contraindications to ESWT (e.g., cardiac pacemaker, malignancy at treatment site)
- Inability to complete treatment or follow-up schedule
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: High-frequency short-course extracorporeal shock wave therapy (ESWT)
Participants receive daily ESWT for 7 consecutive days (7 total sessions within 1 week).
Standard treatment parameters for each session: 2000 shocks, 10 Hz frequency, energy flux density of 0.1-0.25 mJ/mm² (adjusted gradually per patient tolerance).
The treatment site is the most tender area over the rotator cuff, confirmed by palpation and ultrasound guidance.
All participants also receive standardized activity modification guidance and home rehabilitation exercises.
Oral non-steroidal anti-inflammatory drugs (NSAIDs) are permitted and recorded; other physical therapies are prohibited during active treatment.
|
Arm 1: 7 daily sessions, 1 total week (single short cycle) Arm 2: 3 cycles of 7 daily sessions + 1-week rest between cycles, 7 total weeks (intensive multi-cycle) Arm 3: 7 weekly sessions, 7 total weeks (traditional low-frequency)
|
|
Experimenteel: High-frequency intensive ESWT
Participants complete 3 cycles of ESWT.
Each cycle consists of 7 consecutive daily ESWT sessions, with a 1-week rest interval between cycles (21 total sessions over 7 weeks).
Identical ESWT parameters are used for every session: 2000 shocks, 10 Hz frequency, energy flux density of 0.1-0.25 mJ/mm² (adjusted per patient tolerance), targeting the tender rotator cuff area confirmed by ultrasound.
All participants receive unified activity advice and home rehabilitation exercises.
Oral NSAIDs are allowed and documented; additional physical therapies are not permitted during treatment.
|
Arm 1: 7 daily sessions, 1 total week (single short cycle) Arm 2: 3 cycles of 7 daily sessions + 1-week rest between cycles, 7 total weeks (intensive multi-cycle) Arm 3: 7 weekly sessions, 7 total weeks (traditional low-frequency)
|
|
Actieve vergelijker: Conventional ESWT (Active Comparator)
Participants receive ESWT once per week for 7 consecutive weeks (7 total sessions over 7 weeks).
Each session uses the same standardized parameters as the other two arms: 2000 shocks, 10 Hz frequency, energy flux density of 0.1-0.25 mJ/mm², with the treatment location guided by palpation and ultrasound.
All participants follow the same activity modification instructions and home exercise program.
Oral NSAIDs are permitted (recorded), and other physical interventions are restricted during the active treatment period.
|
Arm 1: 7 daily sessions, 1 total week (single short cycle) Arm 2: 3 cycles of 7 daily sessions + 1-week rest between cycles, 7 total weeks (intensive multi-cycle) Arm 3: 7 weekly sessions, 7 total weeks (traditional low-frequency)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in 100-mm Visual Analog Scale (VAS) score for shoulder pain
Tijdsspanne: Baseline (pre-treatment) and 3 months after completion of intervention
|
The primary outcome is the change in active shoulder abduction pain intensity measured via a 100-mm Visual Analog Scale (VAS; 0 = no pain, 100 = worst imaginable pain).
Comparisons are made across three treatment groups from baseline to 3 months post-intervention.
|
Baseline (pre-treatment) and 3 months after completion of intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
American Shoulder and Elbow Surgeons (ASES) Score
Tijdsspanne: Baseline, 3 months, 6 months, 12 months post-treatment
|
Change in ASES shoulder functional score from baseline to 3, 6, and 12 months post-intervention.
Higher scores indicate better shoulder function.
|
Baseline, 3 months, 6 months, 12 months post-treatment
|
|
Constant-Murley Score (CMS)
Tijdsspanne: Baseline, 3 months, 6 months, 12 months post-treatment
|
Change in Constant-Murley shoulder function score from baseline to 3, 6, and 12 months post-intervention, to comprehensively evaluate overall shoulder performance.
|
Baseline, 3 months, 6 months, 12 months post-treatment
|
|
Shoulder Range of Motion (ROM)
Tijdsspanne: Baseline, 3 months, 6 months, 12 months post-treatment
|
Changes in active and passive forward flexion, abduction, and external rotation of the shoulder measured by a standard goniometer at follow-up time points.
|
Baseline, 3 months, 6 months, 12 months post-treatment
|
|
MRI Signal-to-Noise Ratio (SNR) of Rotator Cuff Tendon
Tijdsspanne: Baseline, 6 months, 12 months post-treatment
|
Quantitative change in MRI signal-to-noise ratio of the torn rotator cuff tendon, reflecting tendon tissue repair status.
|
Baseline, 6 months, 12 months post-treatment
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- M20260472
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .